Business
Update on belrestotug development programme
Update on belrestotug development programme.
About this update from Gsk Plc
[{"type":"text","content":"\n\nIssued: 13 May 2025, London UK\n \nGSK provides update on belrestotug development programme\n \n \n\n\nGSK plc (LSE/NYSE: GSK), with its development partner iTeos Therapeutics, Inc., has confirmed it is ending the development programme for belrestotug, an anti-TIGIT monoclonal antibody. The decision is based on new interim analyses from the phase 2 GALAXIES Lung-201 and GALAXIES H&N-202 studies, which did not meet the established efficacy criteria for continued development. As a result, the collaboration and all belrestotug-containing study cohorts are ending.\n \nGSK in Oncology\nOur ambition in oncology is to help increase overall quality of life, maximise survival and change the course of disease, expanding from our current focus on blood and women's cancers into lung and gastrointestinal cancers, as well as other solid tumours. This includes accelerating priority programmes such as antibody-drug conjugates targeting B7-H3 and B7-H4, and IDRX-42, a highly selective KIT tyrosine kinase inhibitor.\n\nAbout GSK\nGSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.\n \n\n\n\n\nGSK enquiries\n\n\n\n\n\n\n\n\n\n\n\n\n\nMedia:\n\n\nTim Foley\n\n\n+44 (0) 20 8047 5502\n\n\n(London)\n\n\n\n\n\n\n\nSarah Clements\n\n\n+44 (0) 20 8047 5502\n\n\n(London)\n\n\n\n\n\n\n\nKathleen Quinn\n\n\n+1 202 603 5003\n\n\n(Washington DC)\n\n\n\n\n\n\n\nLyndsay Meyer\n\n\n+1 202 302 4595\n\n\n(Washington DC)\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\nInvestor Relations:\n\n\nConstantin Fest\n\n\n+44 (0) 7831 826525\n\n\n(London)\n\n\n\n\n\n\n\nJames Dodwell\n\n\n+44 (0) 20 8047 2406\n\n\n(London)\n\n\n\n\n\n\n\nMick Readey\n\n\n+44 (0) 7990 339653\n\n\n(London)\n\n\n\n\n\n\n\nSteph Mountifield\n\n\n+44 (0) 7796 707505\n\n\n(London)\n\n\n\n\n\n\n\nJeff McLaughlin\n\n\n+1 215 751 7002\n\n\n(Philadelphia)\n\n\n\n\n\n\n\nFrannie DeFranco\n\n\n+1 215 751 3126\n\n\n(Philadelphia)\n\n\n\n\n \nCautionary statement regarding forward-looking statements\nGSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limi...